Table 4.
Multivariate Logistic Regression Analysis of Factors Associated with CVD Risk Factors, SPHMMC, Addis Ababa, 2020
| Crude OR | 95% CI | P-value | Adjusted OR | 95% CI | P-value | |
|---|---|---|---|---|---|---|
| Hypertension | ||||||
| Age group | 0.006 | 0.049* | ||||
| <40 | 1 (R) | 1 (R) | ||||
| 40–59 | 3.63 | 1.62–8.13 | 0.002 | 2.52 | 1.11–5.68 | 0.027* |
| ≥60 | 3.64 | 1.17–11.28 | 0.025 | 3.59 | 1.08–11.95 | 0.037* |
| Male gender | 0.41 | 0.23–0.73 | 0.003 | 2.767 | 1.37–5.59 | 0.005* |
| BMI | 0.091 | 0.022* | ||||
| Underweight | 1 (R) | 1 (R) | ||||
| Normal | 3.12 | 0.69–14 | 0.138 | 4.06 | 0.84–19.72 | 0.082 |
| Overweight | 3.53 | 0.77–16.24 | 0.105 | 5.26 | 1.02–27.05 | 0.047* |
| Obese | 6.95 | 1.15–31.23 | 0.019 | 13.79 | 2.29–83.17 | 0.004* |
| Previous ART regimen | 4.13 | 1.71–9.93 | 0.005 | 1.14 | 0.23–5.76 | 0.538 |
| Current ART regimen | 2.46 | 1.11–5.44 | 0.144 | 1.21 | 0.33–4.4 | 0.436 |
| Elevated blood glucose | ||||||
| Age | 0.015 | 0.056 | ||||
| <40 | 1 (R) | 1 (R) | ||||
| 40–59 years | 2.08 | 1.2–3.6 | 0.009 | 2.34 | 1.16–4.7 | 0.017 |
| ≥60 | 2.79 | 1.15–6.75 | 0.023 | 2.13 | 0.71–6.4 | 0.179 |
| Elevated LDL cholesterol | 1.79 | 1.08–2.98 | 0.024 | 0.85 | 0.4–1.83 | 0.683 |
| Elevated total cholesterol | 2.07 | 1.24–3.46 | 0.006 | 2.15 | 0.97–4.77 | 0.061 |
| Current ART regimen | 0.25 | 0.11–0.6 | 0.001 | 0.32 | 0.11–0.96 | 0.092 |
| Previous ART regimen | 0.49 | 0.2–1.21 | 0.194 | 0.37 | 0.6–2.24 | 0.68 |
| CD4 count | 0.32 | 0.08–1.25 | 0.09 | 0.148 | ||
| <200 | 1 (R) | 1 (R) | ||||
| 200–349 | 0.44 | 0.13–1.47 | 0.183 | 0.28 | 0.07–1.2 | 0.087 |
| 350–499 | 1.41 | 0.48–4.17 | 0.53 | 0.86 | 0.23–3.2 | 0.819 |
| ≥ 500 | 1.06 | 0.39–2.89 | 0.91 | 0.68 | 0.19–2.4 | 0.550 |
| Dyslipidemia | ||||||
| Age group | <0.001 | <0.001* | ||||
| <40 | 1 (R) | 1 (R) | ||||
| 40–59 years | 3.08 | 1.76–5.38 | <0.001 | 3.61 | 1.95–6.72 | <0.001* |
| ≥60 | 2.4 | 0.91–6.33 | 0.077 | 2.45 | 0.86–7.01 | 0.094 |
| Hypertension | 1.54 | 0.8–2.95 | 0.193 | 1.06 | 0.5–2.28 | 0.873 |
| BMI | 0.031 | 0.044* | ||||
| Underweight | 1 (R) | 1 (R) | ||||
| Normal | 1.29 | 0.54–3.06 | 0.565 | 1.53 | 0.6–3.9 | 0.375 |
| Overweight | 3.06 | 1.19–7.86 | 0.02 | 3.67 | 1.3–10.1 | 0.014* |
| Obese | 1.75 | 0.57–5.32 | 0.327 | 2 | 0.58–6.86 | 0.277 |
| Elevated blood glucose | 1.2 | 0.66–2.17 | 0.036 | 1.13 | 0.59–2.17 | 0.097 |
| Obesity | ||||||
| Age | 0.761 | 0.941 | ||||
| <40 | 1 (R) | 1 (R) | ||||
| 40–59 years | 1.34 | 0.62–2.94 | 0.998 | 1.18 | 0.47–2.98 | 0.727 |
| Hypertension | 2.32 | 1.03–5.18 | 0.041 | 2.1 | 0.85–5.23 | 0.11 |
| Previous ART regimen (TDF + 3TC + NVP) | 9.05 | 3.01–27.23 | <0.01 | 7.88 | 2.55–24.32 | <0.001* |
| Metabolic syndrome | ||||||
| Age | 0.039 | 0.051 | ||||
| <40 | 1 (R) | 1 (R) | ||||
| 40–59 years | 2.43 | 1.2–4.91 | 0.013 | 2.04 | 0.87–4.78 | 0.101 |
| ≥60 | 2.61 | 0.89–7.61 | 0.079 | 5 | 1.31–19.03 | 0.018 |
| CD4 count | 0.199 | 0.187 | ||||
| <200 | 1 (R) | 1 (R) | ||||
| 200–349 | 0.2 | 0.04–0.99 | 0.049 | 0.15 | 0.03–0.85 | 0.032 |
| 350–499 | 0.76 | 0.21–2.72 | 0.672 | 0.53 | 0.13–2.12 | 0.372 |
| ≥ 500 | 0.64 | 0.2–2.04 | 0.455 | 0.53 | 0.15–1.83 | 0.315 |
| BMI | 0.05 | 0.029* | ||||
| Underweight | 1 (R) | 1 (R) | ||||
| Normal | 4.55 | 0.58–35.7 | 0.15 | 4.02 | 0.49–32.68 | 0.194 |
| Overweight | 8.24 | 1.04–65.37 | 0.046 | 9.35 | 1.13–77.54 | 0.038* |
| Obese | 11.2 | 1.26–99.26 | 0.03 | 12.17 | 1.28–115.5 | 0.03* |
Note: *P-value <0.05.
Abbreviations: 3TC, Lamivudine; BMI, Body mass index; CD4, Cluster of differentiation 4; NVP, Nevirapine; OR, odds ratio; R, Reference; TDF, Tenofovir Disoproxil Fumarate.